. There were 61,256 adult patients receiving renal replacement therapy (RRT) in the UK on 31st December 2015, an absolute increase of 3.9% from 2014. . The actual number of patients increased by 3.6% for haemodialysis (HD), 4.7% for those with a functioning transplant but decreased by 0.8% for peritoneal dialysis (PD). . The UK adult prevalence of RRT was 941 per million population (pmp). The reported prevalence in 2000 was 523 pmp.
. The number of patients receiving home HD decreased slightly from 1,195 patients in 2014 to 1,175 patients in 2015. . The median age of prevalent patients was 59 years (HD 67 years, PD 64 years, transplant 54 years).
In 2000 the median age was 55 years (HD 63 years, PD 58 years, transplant 48 years). The percentage of RRT patients aged greater than 75 years in 2015 was 16.1%. . For all ages, RRT prevalence in men exceeded that in women, peaking in age group 75-79 years at 3,074 pmp in men and at 1,589 pmp in women. . The most common identifiable renal diagnosis was glomerulonephritis (19%), followed by diabetes (16%), other (16%) and aetiology uncertain (16%). . Transplantation continued as the most common treatment modality (53%), HD was used in 41% and PD in 6% of RRT patients. . RRT prevalence in patients aged 585 years continued to increase between 2014 and 2015 (1,060 to 1,084 per million age related population).
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Introduction
This chapter presents data on all adult patients on RRT in the UK at the end of 2015. The UK Renal Registry (UKRR) received data returns for 2015 from all five renal centres in Wales, all five in Northern Ireland and 51 in England. Cambridge (Addenbrooke's) renal centre were unable to submit their 2015 data at patient level by the close of the data collection period. The centre was able to submit summary numbers of patients on RRT at the end of 2015 by treatment modality. Data from all nine centres in Scotland were obtained from the Scottish Renal Registry. Demographic data on children and young adults can be found in chapter 4.
These analyses of prevalent RRT patients are performed annually to aid clinicians and policy makers in planning future RRT requirements in the UK. It is important to understand national, regional and centre level variation in numbers of prevalent patients as part of the capacity planning process. In addition, knowledge about variation in case mix is also reported to improve understanding of where resources should be focussed to improve equity of provision of RRT in the UK.
The term established renal failure (ERF) used within this chapter is synonymous with the terms end stage renal failure and end stage renal disease, which are in more widespread international usage. Patients have disliked the term 'end stage' which reflects the inevitable outcome of this disease.
Methods
Crude prevalence ratios were calculated per million population (pmp) and age/gender standardised prevalence ratios were calculated as detailed in appendix D: Methodology used for Analyses of Clinical Commissioning Group (CCG)/Health Board (HB) Incidence and Prevalence Rates and of Standardised Ratios. (www.renalreg.org).
Throughout this chapter, haemodialysis refers to all modes of HD treatment, including haemodiafiltration (HDF). Several centres reported significant numbers of patients on HDF, but other centres did not differentiate this treatment type in their UKRR returns. Where joint care of renal transplant recipients between the referring centre and the transplant centre occurred, the patient was usually allocated to the referring centre (see appendix B2 for the allocation procedure). Thus the number of patients allocated to a transplant centre is often lower than that recorded by the centre itself and as a converse pre-emptively transplanted patients are sometimes allocated to the transplanting centre rather than the referring centre if no transfer out code had been received. Queries and updated information are welcomed by the UKRR at any point during the year if this has occurred.
Prevalent patients on RRT in 2015 were examined by time on RRT, age group, gender, ethnic origin, primary renal disease, presence of diabetes and treatment modality (see appendix H: Coding) (www.renalreg.org). In the analysis of prevalence, only adult patients on RRT contributed to the numerator and denominator.
Time on RRT was defined as median time on treatment and was calculated from the most recent start date. Patients without an accurate start date were excluded from this calculation.
Analyses were done for the UK as a whole, by UK country, at centre level and split by treatment modality when appropriate. Cambridge is excluded from centre level prevalent analyses.
Chi-squared test, Fisher's exact test, linear regression and Kruskal Wallis tests were used as appropriate to test for significant differences between groups. The data were analysed using SAS 9.3.
Results

Prevalent patient numbers and changes in prevalence
The number of patients for each country (table 2.1) was calculated by adding the number of patients in each renal centre located in the country. These differ marginally from those quoted elsewhere in this report, however, when patients are allocated to geographical areas by their individual postcodes, as some centres treat patients across national boundaries. There were 61,256 adult patients receiving RRT in the UK at the end of 2015, giving an adult UK population prevalence of 941 pmp (table 2.1) compared with 913 pmp in 2014. RRT prevalence increased in all UK countries in 2015. The prevalence of dialysis increased slightly in the UK from 430 pmp in 2014 to 440 pmp in 2015 and there continued to be a slow decline in PD prevalence (55 pmp in 2015 compared with 56 pmp in 2014 and 57 pmp in 2013). This decline in PD prevalence in the UK has been noted since 1997. Conversely, the prevalence of transplanted patients continued to increase in the UK from 482 pmp in 2014 to 501 pmp in 2015. In analyses stratified by country and age group, Northern Ireland exhibited a higher RRT prevalence for patients aged 75 years and older compared with the other UK countries (figure 2.1). In the UK, RRT prevalence in patients aged 80-84 continued to rise from 2,006 per million age related population (pmarp) in 2014 to 2,044 pmarp in 2015 and in patients aged 585 years from 1,060 pmarp in 2014 to 1,084 pmarp in 2015. This trend has been remarked upon over a number of years and the observed aging of the prevalent population is likely due in part to improving patient survival.
Prevalent patients by RRT modality and centre There was a marked variation in the number of prevalent patients across renal centres and the distribution of their treatment modalities varied widely (table 2. 2).
Changes in prevalence
The prevalent UK RRT population grew by 4.3% between 2014 and 2015 (table 2. 3), an annual growth rate which has been fairly consistent over the last 10-15 years (figure 2.2).
The increase in prevalence was smallest in England (4.0%) and greatest in Wales (6.4%). In the case of the latter, this increase was due in part to the way in which Bangor reported transplant patients -previously these were reported by Liverpool Royal with whom Bangor shares the care of its transplant patients. The changes reported here between 2013 and 2014 will differ from those presented in the 18th Annual Report as the current report includes data updates made subsequent to publication of the 18th Annual Report.
The number of prevalent HD patients increased by 2.7% in 2015 compared with 2014 (table 2.4) which was a greater increase than that seen between 2013 and 2014 (1.3% growth in prevalence pmp). There continued to be an increase in prevalent transplant patients (3.9% pmp) and a decrease in prevalent PD patients (1.6% pmp decrease).
The average annual change in prevalent patients between 2011 and 2015 was a 1.3% pmp increase in HD, 2.1% pmp fall in PD, and 4.8% pmp growth in prevalent transplant patients (table 2.4). In the same period there was an average annual 14.9% pmp growth in the use of home haemodialysis (data not shown).
The long-term (1998-2015) UK prevalence pattern by treatment modality is shown in figure 2.2. The steady growth in transplant numbers was maintained in 2015. The increase in home haemodialysis patient numbers over this period has been associated with more than a doubling in prevalence, from 2.0% of the dialysis popu The need for RRT depends upon many factors such as primary renal diagnosis but also on social and demographic factors such as age, gender, social deprivation and ethnicity. Hence, comparison of crude prevalence ratios by geographical area can be misleading. This section, as in previous reports, uses age and gender standardisation to compare RRT prevalence. The ethnic minority profile is also provided to help understand the differences in standardised prevalence ratios (SPRs).
There were substantial variations in the crude CCG/ HB prevalence ratios pmp, from 631 pmp (NHS Guildford and Waverley, population 206,100) to 1,741 pmp (NHS Brent, population 324,000). There were similar variations in the standardised prevalence ratios (ratio of observed: expected prevalence given the age/gender breakdown of the CCG/HB) from 0.64 (NHS South As has been seen in previous years, they tend to reflect the demographics of the regions in question such that urban, ethnically diverse populations in areas of high social deprivation have the highest prevalence of renal replacement therapy. For example, the association with the level of ethnic diversity is illustrated by the fact that mean SPRs were significantly higher in the 89 CCGs/HBs with an ethnic minority population 510% than in those with lower ethnic minority populations (p , 0.001). There was a strong, positive correlation between the SPR and percentage of the population that are non-White (r = 0.9 p , 0.001). In 2015, for each 10% increase in ethnic minority population, the standardised prevalence ratio increased by 0.17 (equates to 17%). These trends are identical to those identified previously. The relationship between the ethnic composition of a CCG/HB and its SPR is demonstrated in figure 2 .3.
Only four of the 146 CCGs/HBs with ethnic minority populations of less than 10% had high SPRs: Abertawe Bro Morgannwg University and Cwm Taf in Wales, Greater Glasgow and Clyde in Scotland, and Belfast in Northern Ireland. Forty-four (49.4%) of the 89 CCGs/ HBs with ethnic minority populations greater than 10% had high SPRs, whereas eight (9.0%) (NHS Chiltern, NHS Brighton and Hove, NHS Richmond, NHS Havering, NHS Solihull, NHS Calderdale, NHS Newcastle and Gateshead, NHS Trafford) had low SPRs. Some of the CCGs/HBs with a high (.15%) ethnic minority population had a normal expected RRT prevalence (e.g. NHS Crawley, NHS Kingston, NHS Milton Keynes, NHS Sheffield, NHS South Manchester).
The age and gender standardised prevalence ratios (which do not take into account variation in ethnicity) in each region of England and in Wales, Northern Ireland and Scotland are presented in table 2.6. Wales and Northern Ireland previously had higher than expected RRT prevalence but in more recent years were similar RRT prevalence in London remained higher than expected.
Case mix in prevalent RRT patients
Time on RRT (vintage) Table 2 .7 shows the median time, in years, since starting RRT of prevalent RRT patients on 31st December 2015. Median time on RRT for all prevalent patients remained fairly static at 6.2 years (6.1 years in 2014). Patients with functioning transplants had survived a median of 10.2 years on RRT whilst the median time on RRT of HD and PD patients was significantly less (3.3 and 1.6 years respectively).
The median time on HD was more than double that on PD and this could reflect early transplantation in the latter as well as higher technique failure rates for PD. Time on transplant is the same as observed in 2013 and 2014, but decreased slightly since 2008 (median 10.4 years) which may reflect a trend towards both the use of more marginal donor kidneys (including Donor after Cardiac Death (DCD) kidneys) and transplantation of older recipients in recent years.
Age
The median age of prevalent UK patients on RRT at 31st December 2015 (59.0 years, table 2.8) has remained stable over recent years although it is significantly higher than in 2005 when it was 55.0 years. As observed previously, there were marked differences between modalities; the median age of HD patients (67.2 years) was greater than that of those on PD (64.2 years) and substantially higher than that of transplanted patients (53.8 years). Of the UK prevalent RRT population, 50% were in the 40-64 years age group (table 2.9). The proportion of patients aged 75 years and older varied greatly between countries and was highest in Wales (18.1%) and Northern Ireland (18.3%) and lowest in Scotland (12.5%) (table 2.9). Within countries there were large differences in the proportion of patients aged over 75 (within England these ranged between 9.1% in Liverpool Royal Infirmary and 46.7% in Colchester). In most centres the prevalent PD population was younger than the HD population (table 2.8).
Between-centre differences in the median age of prevalent patients by treatment modality can reflect differing demographics of the catchment populations as well as differing approaches to treatment modalities. For example, Colchester had the highest median age (73.1 years), whilst Belfast and London Guy's the lowest (55.0 years each) (table 2.8). This could reflect either variation in the catchment populations or follow-up of younger transplant patients (as noted above in the case of Belfast). The median age of the non-White dialysis population was lower than the overall dialysis population (62.0 vs 67.2 years, data not shown). The differing age distributions of the transplant and dialysis populations are illustrated in figure 2 .4, demonstrating that the age peak for prevalent dialysis patients was 24 years later than for prevalent transplant patients.
In the UK on 31st December 2015, 65.8% of patients aged less than 65 years on RRT had a functioning transplant (table 2.15), compared with only 31.3% aged 65 years and over. There was a similar pattern in all four UK countries although the proportion of patients aged less than 65 with a functioning transplant in Northern Ireland (75.3%) was much higher than elsewhere.
Gender
The age distributions of males and females were very similar (data not shown). Standardising the age of the O/E -observed/expected prevalence ratio given the age/gender breakdown of each region Bold -higher than expected prevalence ratio UK RRT prevalent patients by using the age and gender distribution of the UK population by CCG/HB (from mid-2015 population estimates), allowed estimation of crude prevalence by age and gender (figure 2.5). This shows a progressive increase in prevalence with age, peaking at 2,270 pmp (similar to the 2,274 pmp estimate in 2014) in the age group 75-79 years then a rapid decline thereafter. Crude RRT prevalence in males exceeded that of females for all age groups. The difference was smallest in younger patients and was greatest from the age of 70 years onwards. RRT prevalence in males was highest in the 75-79 years group (3,074 pmp) and for females also in the same age group at 1,589 pmp. Survival on RRT by gender is described in chapter 5.
Ethnicity
Key to understanding differences in RRT prevalence between regions is understanding the ethnic diversity of however, and only two years ago was 23.0%. Here, completeness of ethnicity data was highest in prevalent transplant patients (39.0%) which likely reflects improved data recording during the intensive work-up for transplantation. In 2015, 22.7% of the prevalent UK RRT population (with ethnicity assigned) were from ethnic minorities (25.0% in England). The proportion of the prevalent UK RRT population (with ethnicity assigned) from ethnic minorities in Wales, Scotland and Northern Ireland was very small, although it should be noted that there was a high level of missing ethnicity data in Scotland as described above. The ONS estimates that approximately 14% of the UK general population is designated as belonging to an ethnic minority [1] . The relative proportion of patients reported to the UKRR as receiving RRT and belonging to an ethnic minority has increased from 14.9% in 2007 to 22.7% in 2015 which may reflect improvements in coding and reporting of ethnicity data as well as an increasing incidence of ERF and increased referral rates in these populations.
Amongst the centres with more than 50% returns there was wide variation in the proportion of patients from ethnic minorities, ranging from 0.4% in Newry to 63.4% in London St Bartholomew's.
Primary renal diagnosis
Primary renal diagnosis (PRD) is associated with patient outcomes and as it could be used for case-mix adjustment, high levels of data completeness is important. Data for PRD were not complete for 2.6% of patients (table 2.11), but there exists a marked inter-centre difference in completeness of data returns. One centre had 540% primary renal diagnosis data coded as uncertain and has been excluded from the between centre analysis and other analyses where PRD is included in the casemix adjustment (Colchester, 47% uncertain PRD); the UK and national totals have been appropriately adjusted. The percentage of patients with uncertain aetiology for the remaining 69 centres providing individual-level data ranged between 4.4% and 31.2%, which is comparable to recent years. No centre had .30% missing data in 2015 and overall rates of incomplete data are improving.
As observed in previous years, glomerulonephritis (GN) was the most common primary renal diagnosis in the 2015 prevalent cohort at 19.1% (table 2.11). Diabetic nephropathy accounted for 16.7% of renal disease in prevalent patients on RRT, although it was more common in the 65 and over year age group compared to the younger group (18.7% vs 15.5%). This contrasted with incident patients where diabetic nephropathy was the predominant diagnostic code in 27.5% of new RRT patients. The frequency of individual primary renal diagnoses varied with age; patients aged under 65 years and younger were more likely to have GN (21.5%) or diabetes (15.5%) and less likely to have renal vascular disease (1.0%) as the cause of their renal failure. This contrasts with older patients (565 years) among whom 6.3% have renal vascular disease as the cause of their renal failure. Uncertain aetiology was a more common cause in this age group than amongst younger patients (18.1% compared with 13.9% amongst patients ,65 years).
As described in previous years, the male : female ratio was greater than 1 : 1 for all primary renal diagnoses (table 2.11). The biggest differences between males and females were for GN (male : female ratio of 2.1), hypertension (2.4) and renal vascular disease (2.0).
Trends in the transplant : dialysis ratio by primary diagnosis differed markedly between older and younger patients. In individuals aged less than 65 years, the renal transplantation to dialysis ratio was greater than 1 in all PRD groups except diabetic nephropathy and renal vascular disease. In those aged 565 years, dialysis was more prevalent than renal transplantation in all PRD groups except polycystic kidney disease (PKD) (table 2.12).
Diabetes
Throughout this section the term 'diabetic nephropathy' is used to denote patients in whom diabetes mellitus is considered to be the primary cause of the kidney disease rather than merely an associated comorbidity. It includes all prevalent patients with type 1 or type 2 diabetes as the primary renal diagnosis (ERA-EDTA coding). This analysis did not differentiate between type 1 and type 2 diabetes as this distinction was not made in the data submitted by most centres.
The number of prevalent patients with diabetic nephropathy has increased steadily over the last number of years and grew by 4.8% to 9,913 in 2015, from 9,456 in 2014, representing 17.1% of all prevalent patients (compared with 13.5% in 2006) (table 2.13). The male : female ratio for diabetic nephropathy was 1.6. The median age at start of RRT for patients with diabetic nephropathy (56 years) was eight years higher than those with other PRDs (48 years), although the median age at the end of 2015 for prevalent patients with diabetic nephropathy was only four years higher than for individuals without diabetic nephropathy. This reflects reduced survival for patients with diabetes compared with patients without diabetes on RRT. This is also supported by the lower median time on RRT for patients with diabetic nephropathy (3.6 years vs 7.3 years for those without diabetic nephropathy) and this difference in survival has not changed over the last five years (3.4 years vs 6.5 years in 2010). The age at starting RRT in those with diabetic nephropathy was four years younger in Scotland compared with the UK average (data not shown).
There were large differences in the distribution of treatment modalities in those with diabetic nephropathy compared with those without. Fifty eight percent of patients with diabetic nephropathy were undergoing HD compared with just 37% of patients with any other primary renal diagnosis (table 2.13). The percentage of patients with a functioning transplant was much lower in prevalent patients with diabetic nephropathy than in prevalent patients without (34% vs 58%). However, the proportion of patients with diabetic nephropathy with a functioning transplant has increased since 2005 when only 26.9% of patients with diabetic nephropathy had a functioning transplant. For older patients with diabetic nephropathy (age 565 years), only 14.0% had a functioning transplant compared with 48.1% of their peers with other primary diagnoses (table 2.14). In the UK, 34.0% of prevalent patients with diabetic nephropathy had a functioning transplant compared with the UK average of 58.0% amongst those with other primary diagnoses. Amongst those patients receiving dialysis, a higher proportion of prevalent patients without diabetic nephropathy (18.0%) were on home dialysis therapies (home HD and PD) compared with prevalent patients with diabetic nephropathy (13.8%).
Modalities of treatment
Transplantation was the most common treatment modality (53.1%) for prevalent RRT patients in 2015, followed closely by centre-based HD (39.0%) in either hospital centre (17.8%) or satellite unit (21.2%) (figure 2.6). Satellite HD was again more prevalent than in-centre HD, a trend first noted in 2012. Home therapies made up the remaining 7.9% of treatment therapies, largely PD in its different formats (5.9%) which followed a similar pattern since 2012. The proportion on continuous ambulatory peritoneal dialysis (CAPD) and automated PD (APD) was 2.5% and 3.4% respectively, although the proportion on APD may be an underestimate due to centre level coding issues which meant the UKRR could not always distinguish between these therapies. Figure 2 .7 shows the distribution of RRT modalities by age group. From the age of 45 years onwards, transplant prevalence declined as HD prevalence increased. The proportion of each age group treated by PD remained relatively stable.
As the HD prevalence varied by age group, the proportion of prevalent dialysis patients receiving HD varied between centres ranging from 68.1% in Carlisle to 100% in Colchester (table 2.16).
Of the dialysis population, 45.2% received their treatment at a satellite haemodialysis unit in 2015. This figure remains comparable to recent years, but represents an increase from 39.9% in 2010. In 2015, the number of centres that had more than 50% of their haemodialysis activity taking place in satellite units was 27 (figure 2.8).
Although there are satellite units in Scotland, the data provided for 2015 did not distinguish between main centre and satellite unit haemodialysis. As such, it is difficult to accurately assess access to satellite haemodialysis across the UK as a whole, so the statistics pool only England, Wales and Northern Ireland data.
There was also wide variation between centres in the proportion of dialysis patients being managed with APD, ranging from 0.0% to 24.2% ( in Northern Ireland nearly all PD patients were on APD, across the UK six of the 69 centres with a PD programme did not report having any patients on APD.
Home haemodialysis
In 2015, the percentage of dialysis patients receiving home HD varied from 0% in six centres, to greater than 5% in 23 centres (table 2.16). In the UK, the overall percentage of dialysis patients receiving home haemodialysis has increased from 2.9% in 2010 to 4.2% in 2015.
The proportion of dialysis patients receiving home haemodialysis was greatest in Wales at 6.7%, compared with 2.8% in Northern Ireland, 4.3% in England and 2.6% in Scotland (figure 2.8, table 2.16). By comparison, in 2007, the proportion of patients receiving home haemodialysis was 2% in each of the four UK countries. More recently, thirty-five renal centres across the UK had an increase in the proportion of individuals on home haemodialysis compared with 2014. Some patients are sent by their parent renal centre to centres known to have a strong programme for home HD. In order to avoid the possibility of the parent renal centre being wrongly penalised, the proportion of patients on home HD was measured by centre, by assigning the patients to a given centre based on the patient postcode, rather than to the centre that returned the data to the UKRR (table 2.16 -Geo-HHD). This showed an increase in the prevalence of .1% of the home HD for some centres (Doncaster, Dorset, Dudley, Gloucester, London Kings, Liverpool Aintree, Reading, Shrewsbury, Wolverhampton, Antrim, Airdrie and Bangor).
Change in modality
The relative proportion of RRT modalities in prevalent patients has changed dramatically over the past 16 years. The main features are depicted in figure 2.9, which describes a year on year decline in the proportion of patients treated by PD since 2000 and a drop of 6.1% over the last 10 years. The absolute number of patients on PD decreased from 4,471 patients in 2005 to 3,545 patients in 2015. Time on PD has decreased over the last six years, from a median of 2.0 years in 2007 to 1.6 years in 2015 probably reflecting increased transplantation rates in this largely younger patient group and reducing technique survival rates. The percentage of patients undergoing PD for more than seven years was only 8.6%.
The proportion of all RRT patients being treated with HD has fallen slightly since 2009 from 44.1% to 40.9% though this still represents an increase in absolute numbers on HD (from 21,671 to 25,024) as well as an increase in HD prevalence (from 354 to 384 pmp).
The proportion of patients with a functioning transplant has been increasing since 2007 (46.5%) to 53.1% in 2015. This probably reflects both an increasing number of incident transplants (2,218 adults and children in 2007 [2] to 3,174 in 2015) as well as increasing survival of prevalent transplant patients. Figure 2 .10 depicts in more detail the modality changes in the prevalent dialysis population during this time. The data show a clear reduction in patients treated by CAPD over time and an increase in satellite HD coupled with a reduction in hospital HD.
International comparisons
There are marked differences in RRT prevalence between countries (figure 2.11). RRT prevalence in Northern European countries (including the UK), Australia and New Zealand was lower than in Southern Europe which was lower than the USA and Canada. Identifying the source of these differences is complicated by differences in healthcare systems, patient registry coverage and definitions (for example, data from Japan only includes dialysis), approaches to conservative care and incidence rates in these countries.
Discussion
The proportion of adults undergoing RRT continued to grow across all countries in the UK and there was an increase of 4% on 2014 in the UK as a whole.
Whilst half of all patients on RRT continued to be aged 40-64 years, the prevalent population is becoming more elderly with 16% of patients being over 75 years compared to 15.1% in 2010. This is most noticeable in transplant patients where 31% of over 65 year old patients had a working transplant in 2015 compared to 23.7% in 2010.
The proportion of patients using peritoneal dialysis has been falling since the early 1990s and was just 6% in 2015.
There were large variations in RRT prevalence between CCG/HB across the UK. This variation will largely be determined by the number of patients needing RRT but also by the clinical care delivered by renal centres. Many factors unrelated to clinical care will also have contributed to these differences such as geography, local population density, age distribution, ethnic composition, prevalence of diseases predisposing to kidney disease and the social deprivation index of that population. Comparisons with previous years was hindered somewhat by changes in the lower super output areas (LSOAs) 'covered' by each CCG as well as the combining of CCGs (in 2015 Gateshead CCG, Newcastle North and East CCG and Newcastle West CCG merged). The percentage of CCG/HB areas with prevalence ratios as expected for the age and gender distribution of each area has increased over the last five years with fewer areas having higher than expected ratios. The reorganisations seen in healthcare areas over this same time period make interpretation of this finding more difficult. There remained large variations in the numbers of patients receiving RRT in each health area in the UK and the effects of centralising specialist commissioning arrangements in England on this variation will be seen in subsequent years.
